392 related articles for article (PubMed ID: 31101027)
1. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
Yang X; Zhang K; Zhang C; Peng R; Sun C
BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
Zhou Y; Wang C; Zhu H; Lin Y; Pan B; Zhang X; Huang X; Xu Q; Xu Y; Sun Q
PLoS One; 2016; 11(6):e0158143. PubMed ID: 27336598
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.
Xie W; Xie L; Song X
Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
Luo J; Shen L; Zheng D
Sci Rep; 2014 Sep; 4():6269. PubMed ID: 25201768
[TBL] [Abstract][Full Text] [Related]
5. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.
Lin Z; Neiswender J; Fang B; Ma X; Zhang J; Hu X
Oncotarget; 2017 Apr; 8(16):26625-26636. PubMed ID: 28460452
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.
Li B; Pu K; Ge L; Wu X
Gene; 2019 Sep; 714():143993. PubMed ID: 31330238
[TBL] [Abstract][Full Text] [Related]
7. Cell-Free DNA Variables including Gene Mutations in CA15-3 Normal Breast Cancer Reflect Prognosis.
Xu J; Chen W; Sun Z; Peng H; Zhou C; Pan S
Dis Markers; 2022; 2022():5470166. PubMed ID: 35251373
[TBL] [Abstract][Full Text] [Related]
8. Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer-Related Single-Nucleotide Variants and Copy Number Variants Using Simulated Cell-Free DNA.
Yang X; Chu Y; Zhang R; Han Y; Zhang L; Fu Y; Li D; Peng R; Li D; Ding J; Li Z; Zhao M; Zhang K; Lu T; Yi L; Wu Q; Lin G; Xie J; Liu T; Yang L; Yi X; Li J
J Mol Diagn; 2017 Jul; 19(4):525-536. PubMed ID: 28502728
[TBL] [Abstract][Full Text] [Related]
9. Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer.
Shen N; Zhang D; Yin L; Qiu Y; Liu J; Yu W; Fu X; Zhu B; Xu X; Duan A; Chen Z; Wang X; Cao X; Zhao T; Zhou Z; Yu L; Qin H; Fang Z; Li JY; Liu Y; Xiong L; Yuan B; Li F; Zhang Y
Oncol Rep; 2019 Aug; 42(2):549-560. PubMed ID: 31173267
[TBL] [Abstract][Full Text] [Related]
10. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
11. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
[TBL] [Abstract][Full Text] [Related]
12. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M
Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316
[TBL] [Abstract][Full Text] [Related]
13. Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.
Jansen MP; Martens JW; Helmijr JC; Beaufort CM; van Marion R; Krol NM; Monkhorst K; Trapman-Jansen AM; Meijer-van Gelder ME; Weerts MJ; Ramirez-Ardila DE; Dubbink HJ; Foekens JA; Sleijfer S; Berns EM
Oncotarget; 2016 Jul; 7(28):43412-43418. PubMed ID: 27270325
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
[TBL] [Abstract][Full Text] [Related]
15. SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA.
Kockan C; Hach F; Sarrafi I; Bell RH; McConeghy B; Beja K; Haegert A; Wyatt AW; Volik SV; Chi KN; Collins CC; Sahinalp SC
Bioinformatics; 2017 Jan; 33(1):26-34. PubMed ID: 27531099
[TBL] [Abstract][Full Text] [Related]
16. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
[TBL] [Abstract][Full Text] [Related]
17. A Case-Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection.
Bortul M; Giudici F; Tierno D; Generali D; Scomersi S; Grassi G; Bottin C; Cappelletti MR; Zanconati F; Scaggiante B
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239866
[TBL] [Abstract][Full Text] [Related]
18. The assessment of circulating cell-free DNA as a diagnostic tool for breast cancer: an updated systematic review and meta-analysis of quantitative and qualitative ssays.
Guo Q; Hua Y
Clin Chem Lab Med; 2021 Aug; 59(9):1479-1500. PubMed ID: 33951758
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of cell-free DNA in thyroid cancer: A systematic review and meta-analysis.
Hou F; Sun XD; Deng ZY
Medicine (Baltimore); 2023 Feb; 102(7):e32928. PubMed ID: 36800605
[TBL] [Abstract][Full Text] [Related]
20. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Iwase H
Cancer Biomark; 2018; 22(2):345-350. PubMed ID: 29689710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
